I see where this is going. The fda will reassign the original acronym to another disease, immediately rendering all of our previous trials and protocols useless because they’re now for the wrong disease. We have to start over from phase 1 and the fda requests a type f(u) meeting to discuss what’s needed. That meeting gets set for early 2025 because the fda is backlogged on type f(u) meetings.